Commentary: What Does Sale of DaVita Medical Group Mean for Berkshire Hathaway?

(BRK.A), (BRK.B)

The news that health services company Optum is purchasing DaVita Medical Group, a subsidiary of DaVita Inc., for $4.9 billion may bring a windfall for Berkshire Hathaway.

Berkshire has a $2.27 billion stake in DaVita Inc., which works out to roughly 22.03% of the company’s market cap and approximately 23.57% of the institutional ownership, and news of the sale gave Berkshire an immediate paper profit boost of $230 million.

The longer term prospect is good for Berkshire, as well.

According to DaVita, the company plans to use the proceeds from the transaction for significant stock repurchases over the one to two years following the closing of the transaction, as well as to repay debt and for general corporate purposes.

“Following this transaction, DaVita will continue to be a leader in population health management, with a focus on our U.S. and international kidney care businesses,” DaVita CEO Kent Thiry said. “We also expect to pursue other investments in health care services outside of kidney care.

Berkshire has long been rumored to be interested in acquiring DaVita, and entered into a standstill agreement with Davita in May 2014, pledging not purchase more than 25% of the company.

And while Berkshire doesn’t reveal whether Warren Buffett, or his portfolio managers Ted Weschler and Todd Combs, purchased or sold a particular security, the push to acquire shares in DaVita is generally credited to Ted Weschler.

It looks like he was right on this one.

© 2017 David Mazor

Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.